AngioDynamics (NASDAQ:ANGO) Downgraded by Zacks Research to “Strong Sell”

Zacks Research cut shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a strong sell rating in a report issued on Thursday morning,Zacks.com reports.

Several other equities analysts also recently issued reports on ANGO. Canaccord Genuity Group boosted their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. HC Wainwright lifted their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, AngioDynamics presently has an average rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Price Performance

Shares of ANGO opened at $13.51 on Thursday. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $15.19. The stock has a fifty day moving average price of $12.24 and a 200 day moving average price of $11.35. The company has a market cap of $558.37 million, a P/E ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The company had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current year.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kotler Kevin acquired a new position in shares of AngioDynamics during the 4th quarter valued at $21,997,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics in the fourth quarter valued at $17,978,000. UBS Group AG lifted its holdings in shares of AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after buying an additional 501,881 shares during the period. Millennium Management LLC boosted its stake in AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares in the last quarter. Finally, Nuveen LLC boosted its stake in AngioDynamics by 40.5% during the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after buying an additional 373,110 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.